TransCode Therapeutics regains Nasdaq minimum bid price compliance; hearing cancelled

Transcode Therapeutics, Inc.

Received Nasdaq letter on June 3, 2024 confirming compliance with Listing Rule 5550(a)(2).
Hearing scheduled for June 25, 2024 has been cancelled.
Remains under mandatory panel monitor through January 27, 2025.
Ticker RNAZ; stock continues on Nasdaq Capital Market.

item 8.01

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-069605

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.